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Improvements in diagnosis and therapy in on-
cology have led to a significantly increased survival
of young males affected by cancer.1 Depending
on the chemotherapeutic agent and the duration
of treatment, however, 45–80% of patients will
develop permanent testicular dysfunction result-
ing in azoospermia. Although the side effects 
of radiation therapy have been ameliorated by
the advent of computerized radiography tech-
niques, and higher dosages can now be delivered
accurately to the target tumor, dosages of radia-
tion treatment > 1–2 Gy are still destructive 
to germinal epithelium. Thus, impairment of
spermatogenesis is an inevitable consequence
following chemotherapy and/or radiotherapy.2,3
Fertility preservation has been included in the
rcomplete treatment plan for every new cance
patient in our hospital for 10 years. Our medical
center now offers the service of sperm cryopreser-
vation for any male cancer patient hoping to pre-
serve his fertility.
fThis retrospective study analyzed the results o
this service during the initial 10 years of its avail-
tability, including cancer type, rates of patien
death, timing of collection, sperm quality and
specimen disposal.
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Offering sperm cryopreservation to preserve the fertility of male cancer patients is a relatively recent service
in Asia. This study analyzed the types of cancer, timing of collection, sperm quality, and utilization for repro-
yductive services by patients during a 10-year period at a medical center in Taiwan. A total of 75 oncolog
fpatients elected to freeze sperm for fertility preservation at our medical center during the initial 10 years o
the availability of this service. The mean age of the patients was 25.7 years. Storage was discontinued in 13
(17%) patients and their survival duration was 13.1 ± 11.1 months. The utilization rate of sperm cryo-
preservation was 2.8% (75/2642). The types of cancer varied, with leukemia (35%), lymphoma (25%),
and testicular cancer (13%) comprising the largest groups. A significantly lower sperm count was found in
patients with chronic myelogenous leukemia, suggesting the need for earlier sperm collection after initia-
tion of cancer treatment. Only three (4%) patients utilized their specimens for reproductive purposes. There
was no clinical pregnancy during the study period, although one biochemical pregnancy was achieved.
The low rates of sperm cryostorage for fertility preservation in tcancer patients in this study suggest tha
there is a need for greater emphasis of this option for male oncology patients whose fertility is likely to be
affected by chemotherapeutic treatment. [J Formos Med Assoc 2006;105(12):1022–1026]
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Methods
Since 1995, our andrology laboratory has provid-
ed a sperm cryopreservation service for oncology
patients. From 1995 to 2004, 112 cancer patients
were referred to our andrology laboratory and 75
patients completed sperm collection for cryobank-
ing. The initial evaluation consisted of collecting
complete information about medical, surgical and
family history. The medical history included can-
cer diagnosis, any previous or recent medication
related to spermatogenesis, and general physical
condition. Information collected on surgical his-
tory consisted of previous surgical intervention
for the cancer such as biopsy, tumor resection, and
port-A catheter implantation. Information on mar-
ital status, prior fertility and family relationships
were included in the family history. For patients
requiring emergent consultation from an oncolo-
gist for acute leukemia, the procedure of evalua-
tion was completed as soon as possible. A signed
detailed consent form that described the benefits
of freezing, future disposal and the potential
risks (i.e. sperm survival or no guarantee of preg-
nancy) was collected from all participants.
Semen specimens were collected in a sterile
wide-opening container by masturbation. Two
days abstinence of ejaculation prior to semen col-
lection was suggested to patients who did not have
a hurried oncology treatment schedule. Upon col-
lection, each semen sample was allowed to liquefy.
The pre-freeze semen sample was analyzed accord-
ing to the 1992 WHO guidelines. The SQA II
(Medical Electronic Systems Ltd., Caesarea, Israel),
a desktop instrument that combines optical detec-
tion with an internal computer, was used to pro-
vide a quantitative evaluation of semen quality.
Sperm cryopreservation was performed ac-
cording to the manufacturer’s recommendations.
Briefly, both the semen sample and the sperm
freezing medium (MediCult, Jyllinge, Denmark)
were kept at room temperature. The semen was
diluted 1:1 (v/v) with the sperm freezing me-
dium. The medium was added drop-wise to the
semen and the solution carefully mixed after
each addition. The resultant mixture was left at
room temperature for a minimum of 10 minutes.
Cryo-tubes were filled with the diluted semen
and sealed according to the manufacturer’s rec-
ommendations. The cryo-tubes were attached to
fa cane and suspended just above the surface o
the liquid nitrogen for 30 minutes. Finally, the
cryo-tubes were submerged in the liquid nitro-
gen for final storage. The quality of the sperm
y freezing procedure was considered satisfactor
if > 40% of the original motility was maintained
after thawing.
Statistical analysis
Statistical analyses were performed using SPSS
version 10.0 (SPSS Inc., Chicago, IL, USA). Mean ±
standard deviation were calculated for all variables.
gContinuous variables were compared amon
groups using Student’s t test to compare two
groups, or using analysis of variance (ANOVA) to
compare multiple groups. All statistical tests were
two-sided, and a value of p < 0.01 was considered
to indicate statistical significance.
Results
From 1995 to 2004, a total of 2642 new male
patients aged 13–45 years at diagnosis were
recorded in the cancer registry of National Taiwan
University Hospital (NTUH). We defined 13–45
years as the reproductive age range during which
ra patient was most likely to have the potential fo
fand desire to preserve fertility. Only 75 (2.9%) o
rthe registered new male patients preserved thei
sperm prior to or during their cancer treatment.
The characteristics of these patients are listed in
Table 1. The majority of patients had leukemia
(35%), testicular cancer (13%) or lymphoma
(13%). Comparison of the age distribution be-
tween each cancer category by ANOVA revealed
no significant difference of mean age (p = 0.29).
There were 69 (92%) patients whose sperm
ywas collected prior to initiation of chemotherap
or radiation therapy. Only six (8%) patients were
referred for sperm cryopreservation after more
than one treatment session, one of these patients
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had acute myelogenous leukemia (AML) and
five had chronic myelogenous leukemia (CML).
Mean sperm count of the 75 patients was
56.3 ± 4.3 × 106/mL, and mean sperm motility was
42.1 ± 1.8%. Compared with these mean values of
all 75 cases, analysis with Student’s t test revealed
a significantly lower sperm count in patients with
CML and patients with extragonadal germ cell
tumor, and a higher sperm count in the sarcoma
group. The motility in the extragonadal germ cell
group was significantly less than the average value
of the total cases.
The percentages of patients with oligosper-
mia (defined as sperm count < 40 × 106/mL) and
asthenospermia (defined as motility < 40%) are
yshown in Table 1. Both sperm count and motilit
were impaired in more than 50% of patients
with CML, extragonadal germ cell tumor, and
testicular cancer. In patients with Hodgkin’s dis-
tease, sperm motility was greatly affected bu
there was no impairment in sperm count.
Storage was discontinued due to death in a
total of 13 (17%) patients (Table 2). The mean
duration of storage for this group was 13.1 ± 11.1
Table 1. Patient characteristics and semen parameters according to cancer type
Cancer type
Patients, Age (yr) at Sperm count Motility Oligospermia* Asthenospermia*
n (%) freeze (range) (×106/mL) (%) (%) (%)
Leukemia
AML 12 (16) 26.9 ± 8.1 (17–44) 69.3 ± 9.4 45.2 ± 3.7 8 25
ALL 8 (11) 22.7 ± 6.4 (15–33) 51.6 ± 5.4 41.2 ± 3.5 25 37
CML 6 (8) 30.3 ± 3.7 (24–33) 19.5 ± 1.7† 36.1 ± 3.8 83 80
Testicular cancer 10 (13) 26.3 ± 8.5 (18–45) 41.8 ± 9.1 32.8 ± 5.3 50 70
Non-Hodgkin’s lymphoma 10 (13) 25.6 ± 7.7 (15–38) 66.0 ± 12.3 50.8 ± 4.4 20 10
Hodgkin’s disease 9 (12) 23.3 ± 6.1 (19–39) 55.7 ± 8.2 36.2 ± 3.3 22 88
Sarcoma 5 (7) 29.8 ± 7.3 (18–36) 90.6 ± 9.8† 50.4 ± 11.0 0 20
Extragonadal germ cell tumor 5 (7) 27.0 ± 5.4 (23–36) 17.6 ± 3.9† 27.2 ± 1.2† 100 100
Other‡ 10 (13) 20.8 ± 6.3 (13–30) 74.6 ± 18.3 51.7 ± 7.0
p§ 0.29
Total 75 25.7 ± 7.4 (13–45) 56.3 ± 4.3 42.1 ± 1.8
*Oligospermia is defined as sperm count < 40 × 106/mL and asthenospermia as sperm motility < 40%; †p < 0.01 compared with total number of cases
(Student’s t test); ‡those cancer categories for which the case number was less than five are summarized in this group (included aplastic anemia, brain
tumor, nasopharyngeal cancer, bladder and prostate cancer); §p values calculated by analysis of variance. AML = acute myelogenous leukemia; ALL = acute
lymphoblastic leukemia; CML = chronic myelogenous leukemia.
Table 2. Characteristics of patients with discontinuation of sperm cryopreservation due to death
Cancer type n Age (yr) at sperm freezing (range) Duration of freezing (mo)
AML 5 30.4 ± 10.9 (17–44) 16.1 ± 16.6 (2.5–44.1)
ALL 4 22.7 ± 7.1 (15–31) 9.8 ± 5.7 (3.2–17.2)
Aplastic anemia 1 30 11
Hodgkin’s disease 1 23 11
Non-Hodgkin’s lymphoma 1 24 8
Bladder cancer 1 28 28
Total 13 26.5 ± 7.9 (15–47) 13.1 ± 11.1 (2.5–44.1)
AML = acute myelogenous leukemia; ALL = acute lymphoblastic leukemia.
months (range, 2.5–44.1 months). The major
types of cancers in these patients were AML and
acute lymphoblastic leukemia.
Only three patients utilized their cryopre-
served sperm for reproductive purposes. A total
of two insemination cycles and three in vitro fer-
tilization (IVF) attempts resulted in only one
biochemical pregnancy. There was no clinical
pregnancy or live birth during the study period.
Discussion
All men who are about to receive cancer treat-
ment that could impair fertility should be coun-
seled about such side effects and given adequate
information to make an informed decision
about sperm cryopreservation.4,5 The percentage
of cancer patients with sperm cryopreservation
in this study (2.9%) is within the 2.6–7.7%
range of previous reports.6–8 Almost all of them
would need IVF with intracytoplasmic sperm in-
jection to overcome poor sperm quality.
In the present study, oligospermia was com-
mon in patients with testicular cancer, CML,
Hodgkin’s disease and extragonadal germ cell
tumor. Previous studies have attributed low
sperm quality to the effects of the tumor on sper-
matogenesis and the production of β-human
chorionic gonadotropin by some cancer histo-
types.9,10 Semen quality tended to be poorer in
men with higher testicular cancer stages.
CML has a rather good prognosis, but > 80%
of the semen collected from our patients were
oligospermic and asthenospermic. In this series,
83% (5/6) of CML patients collected sperm for
cryopreservation after the initiation of more than
one cancer treatment. Sperm storage was not
considered as a necessary management until the
disease went into a blast crisis or accelerated
phase. The delay in fertility consultation in CML
may explain why the sperm quality of these pa-
tients was poorer than in other reports.
The detrimental effect of lymphomas and
their treatment on spermatogenesis is well
established.11 In the present study, we also
demonstrated that these patients had reduced
pretreatment sperm concentrations. Oligospermia
(defined as values < 40 × 106/mL) was found in
22% of patients with Hodgkin’s disease and 20%
with non-Hodgkin’s lymphoma in this series.
Previous studies have found abnormal spermato-
genesis in 40–70% of patients with Hodgkin’s dis-
ease before therapy.12,13 It has been suggested
 that this impairment is related to the presence
of constitutional symptoms and general stress
tassociated with tumoral illness (fever, weigh
loss).14–16
In the past decade, overall 5-year survival rates
(based on cancer registry data from the Office
rof Medical Records at NTUH) for male cance
patients aged < y45 years of age have graduall
improved to 54.7%, but remain lower than in the
United States (79%).17 wAn epidemiologic revie
yconcluded that sperm cryostorage for fertilit
preservation in cancer patients is under-utilized
in the United States.18 Lack of discussion time,
presumed high cost, unavailability of adequate
ffacilities and overestimation of the limitations o
sperm quality were reported as the most common
reasons that sperm banking was not suggested.4,5
From 1995 to 2004, a total of 2642 male pa-
tients < 45 years old had a diagnosis of cancer in
our hospital, but only < 2.9% of these patients
had sperm cryopreservation.
The low overall 5-year survival rate may be
wonly one of the factors responsible for the lo
percentage of cancer patients selecting the op-
tion of sperm preservation in Taiwan. The major-
gity of cancer patients lose interest in preservin
fertility when they are faced with an unpre-
dictable and unfavorable prognosis. The collec-
rtion of ejaculate is often difficult due to poo
ygeneral health condition. The oncologist ma
ralso take a pessimistic view of survival rate fo
patients with aggressive tumors, which impedes
the likelihood of sperm banking.
Comprehensive cancer treatment planning is
gneeded to help oncologists offer sperm bankin
as an option to all men at risk of infertility be-
cause of their cancer or its treatment. Even men
with poor prognosis should be provided with
fSperm cryopreservation services or cancer patients
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the option of cryostorage as a form of psycho-
logic reassurance and planning for recovery.
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